Cover Image
市場調查報告書

細胞性腫瘤抗體P53 (腫瘤抑制劑P53或抗體NY-CO-13):開發中產品分析

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 358696
出版日期 內容資訊 英文 127 Pages
訂單完成後即時交付
價格
Back to Top
細胞性腫瘤抗體P53 (腫瘤抑制劑P53或抗體NY-CO-13):開發中產品分析 Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H2 2016
出版日期: 2016年09月21日 內容資訊: 英文 127 Pages
簡介

本報告提供全球各國治療細胞性腫瘤抗體P53 (腫瘤抑制劑P53或抗體NY-CO-13) 所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要的疾病及藥物概要,最新的產業趨勢等資訊。

目錄

  • 簡介
    • 分析範圍
  • 細胞性腫瘤抗體P53 (腫瘤抑制劑P53/抗體NY-CO-13)的概要
  • 治療藥的開發
    • 臨床實驗中的產品:臨床實驗的各階段
    • 臨床實驗中的產品:各治療領域
    • 臨床實驗中的產品:不同症狀
  • 開發中產品的概要
    • 臨床實驗後期階段的產品
    • 臨床實驗初期階段的產品
  • 各企業開發中的產品
  • 各大學/研究機關開發中的產品
  • 治療藥的評估
    • 單劑治療藥/並用治療藥的情況
    • 各作用機制
    • 各投藥途徑
    • 各分子類型
  • 細胞性腫瘤抗體P53 (腫瘤抑制劑P53/抗體NY-CO-13) 治療藥的開發企業
    • Advaxis, Inc.
    • American Gene Technologies International Inc.
    • Aprea AB
    • Cellceutix Corporation
    • Critical Outcome Technologies Inc.
    • Eleos Inc.
    • ORCA Therapeutics B.V.
    • OSE Pharma SA
    • PCI Biotech Holding ASA
    • Quark Pharmaceuticals, Inc.
    • Stemline Therapeutics, Inc.
    • Shenzen SiBiono GeneTech Co., Ltd.
    • SK Biopharmaceuticals Co., Ltd.
    • Tara Immuno-Oncology Therapeutics LLC
    • Z53 Therapeutics, LLC
  • 藥物簡介
    • Adxs-LmddA159
      • 產品概要
      • 作用機制
      • 研究開發 (R&D)的進展
    • AG-1101
    • APR-017
    • APR-246
    • ATRN-502
    • cenersen sodium
    • contusugene ladenovec
    • COTI-2
    • D-12PGJ3
    • Gene Therapy to Activate p53 for Head and Neck Squamous Cell Carcinoma
    • Gene Therapy to Activate p53 for Oncology
    • KM-3174
    • MHY-449
    • MJ-05
    • MX-225
    • N-2
    • Oncolytic Viruses to Activate p53 for Oncology
    • OSE-2101
    • p28
    • QPAL-1
    • QPI-1002
    • Recombinant Protein to Activate p53 for Oncology
    • SGT-53
    • SL-801
    • Small Molecule to Activate p53 for Cancer
    • Small Molecules to Activate p53 for Cancer and Viral Infections
    • Small Molecules to Activate p53 for Melanoma
    • Vaccine to Target Cellular Tumor Antigen p53 for Oncology
    • ZMC-1
  • 開發暫停的計劃
  • 開發中止的計劃
  • 值得注意的最新趨勢·新聞稿 (全10件)
  • 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0531TDB

Summary

Global Markets Direct's, 'Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H2 2016', provides in depth analysis on Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted pipeline therapeutics.

The report provides comprehensive information on the Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53)
  • The report reviews Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) Overview
  • Therapeutics Development
    • Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Products under Development by Stage of Development
    • Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Products under Development by Therapy Area
    • Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Products under Development by Indication
  • Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Products under Development by Companies
  • Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Products under Development by Universities/Institutes
  • Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Companies Involved in Therapeutics Development
    • Advaxis, Inc.
    • American Gene Technologies International Inc.
    • Aprea AB
    • Cellceutix Corporation
    • Critical Outcome Technologies Inc.
    • Eleos Inc.
    • ORCA Therapeutics B.V.
    • OSE Immunotherapeutics
    • PCI Biotech Holding ASA
    • Quark Pharmaceuticals, Inc.
    • Shenzen SiBiono GeneTech Co., Ltd.
    • SK Biopharmaceuticals Co., Ltd.
    • Stemline Therapeutics, Inc.
    • Tara Immuno-Oncology Therapeutics LLC
    • Z53 Therapeutics, LLC
  • Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Drug Profiles
    • Adxs-LmddA159 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AG-1101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • APR-017 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • APR-246 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ATRN-502 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cenersen sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • contusugene ladenovec - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • COTI-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • D-12PGJ3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate p53 for Head and Neck Squamous Cell Carcinoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate p53 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KM-3174 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MHY-449 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MJ-05 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MX-225 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • N-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Oncolytic Viruses to Activate p53 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OSE-2101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • p28 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • QPAL-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • QPI-1002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Activate p53 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SGT-53 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SL-801 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Target Cdk2, Cdk4, Cdk6, Cyclin D1, Cyclin B1, Cdc2, p53 and p16 for Bacterial Infections and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate p53 for Melanoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate p53 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate p53 for Oncology and Viral Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target Cellular Tumor Antigen p53 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZMC-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Dormant Projects
  • Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Discontinued Products
  • Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Featured News & Press Releases
    • Aug 03, 2016: Cellceutix Prepares Phase 2a Ovarian Cancer Trial of Kevetrin, a Novel p53-Modulating Drug Candidate, Based Upon Phase 1 Topline Data
    • Jul 12, 2016: Critical Outcome Initiates Third Cohort in Phase 1 Study of COTI-2 in Gynecologic Cancers
    • Jun 06, 2016: Critical Outcome Activates Second Clinical Trial Site for Its COTI-2 Gynecological Cancer Study
    • Jun 06, 2016: Cellceutix Announces Database Lock in Phase 1 Trial of Kevetrin, a Promising New Cancer Treatment That Activates p53
    • Jun 06, 2016: Aprea AB Announces Efficacy and Safety Data in High-Grade Serous Ovarian Cancer Patients Treated with Investigational APR-246 Presented at 2016 ASCO Annual Meeting
    • Jun 06, 2016: Cancer drug trial success
    • May 24, 2016: Critical Outcome Receives Additional Patent Protection for Potential Transformational P53 Cancer Treatment
    • May 03, 2016: Stemline Therapeutics Clears First Cohort of Patients in Ongoing SL-801 Phase 1 Trial
    • Apr 27, 2016: Critical Outcome Technologies Augments Advisory Board Drug Development Experience
    • Apr 19, 2016: Critical Outcome Commences Treatment of Second Cohort in Phase 1 Study of COTI-2 in Gynecologic Cancers
    • Mar 31, 2016: Cellceutix Successfully Completes In Vitro Study in Support of Planned Phase 2 Trial of Kevetrin for Ovarian Cancer
    • Mar 14, 2016: Quark Pharmaceuticals Doses First Patient In Two Pivotal Clinical Studies of RNAi-Based Therapeutic QPI-1002
    • Feb 22, 2016: Assay Results From Cellceutix Phase 1 Clinical Trial of Kevetrin for Cancer Show Increased p21 Expression in 67.5% of Evaluable Patients
    • Feb 22, 2016: First patients enrolled and dosed in the pivotal trial of Phase 3 of the immunotherapy Tedopi for advanced non-small cell lung cancer
    • Feb 16, 2016: Critical Outcome Treats First Patient in Phase 1 Study of COTI-2 in Gynecologic Cancers
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by Advaxis, Inc., H2 2016
  • Pipeline by American Gene Technologies International Inc., H2 2016
  • Pipeline by Aprea AB, H2 2016
  • Pipeline by Cellceutix Corporation, H2 2016
  • Pipeline by Critical Outcome Technologies Inc., H2 2016
  • Pipeline by Eleos Inc., H2 2016
  • Pipeline by ORCA Therapeutics B.V., H2 2016
  • Pipeline by OSE Immunotherapeutics, H2 2016
  • Pipeline by PCI Biotech Holding ASA, H2 2016
  • Pipeline by Quark Pharmaceuticals, Inc., H2 2016
  • Pipeline by Shenzen SiBiono GeneTech Co., Ltd., H2 2016
  • Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016
  • Pipeline by Stemline Therapeutics, Inc., H2 2016
  • Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2016
  • Pipeline by Z53 Therapeutics, LLC, H2 2016
  • Dormant Projects, H2 2016
  • Dormant Projects (Contd..1), H2 2016
  • Dormant Projects (Contd..2), H2 2016
  • Dormant Projects (Contd..3), H2 2016
  • Dormant Projects (Contd..4), H2 2016
  • Dormant Projects (Contd..5), H2 2016
  • Dormant Projects (Contd..6), H2 2016
  • Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Top 10 Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top